The head of the Egyptian Drug Authority (EDA) has met with representatives of multinational pharmaceutical companies to discuss mechanisms for strengthening the country’s drug system and supporting investment.
EDA Chairman Dr. Ali El-Ghamrawy affirmed the authority’s keenness to enhance its strategic partnership with the industrial sector and support the stability of the Egyptian pharmaceutical market.
“The stability of the drug market is a national priority and a major focus in supporting the healthcare system,” El-Ghamrawy said in a statement. He explained that the EDA adopts flexible regulatory policies in line with international best practices to ensure the accelerated availability of innovative medicines and increase market competitiveness while maintaining the highest levels of quality and safety.
The EDA stressed that continuous dialogue with global companies is a fundamental pillar for achieving the national vision of developing the drug sector, facilitating supply chains, and supporting the investment climate.
For their part, the representatives of the pharmaceutical companies expressed their appreciation for the EDA’s efforts. They praised the authority’s participatory approach, professionalism, and rapid response, stating that this cooperation paves the way for more investment and opens wider prospects for providing the latest treatments to patients in Egypt.
The meeting was attended by senior EDA officials and representatives from companies including AstraZeneca, Sandoz, Sanofi, Pfizer, and Roche.
